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A B S T R A C T
The pro-inflammatory cytokine LTA (lymphotoxin-α) has multiple functions in regulating the
immune system and may contribute to inflammatory processes leading to CHD (coronary heart
disease). The aim of the present study was to investigate whether the common C804A (resulting
in a Thr26 → Asp amino acid substitution) and A252G polymorphisms of the LTA gene and the
C3279T polymorphism of the galectin-2 (LGALS2) gene, which affects LTA secretion, are associated
with inflammatory parameters and cell adhesion molecules, and whether these polymorphisms
are related to CHD in American women and men. We conducted a prospective nested case-
control study within the Nurses’ Health Study and Health Professionals Follow-Up Study. Among
participants free of cardiovascular disease at baseline, 249 women and 266 men developed CHD
during 8 and 6 years of follow-up respectively, and we matched controls 2:1 based on age and
smoking. The LGALS2 gene variant was significantly associated with a decreased risk of CHD in
women [odds ratio (95% confidence interval), 0.70 (0.50–0.97); P = 0.03]. In addition, the LGALS2
polymorphism was directly associated with CRP (C-reactive protein) levels in cases from both
studies (P < 0.05). The LTA gene polymorphisms were directly associated with levels of sTNFRs
(soluble tumour necrosis factor receptors) and VCAM-1 (vascular cell adhesion molecule-1) in
both women and men with CHD (P < 0.05). However, no overall effect was demonstrated between
LTA gene polymorphisms and risk of CHD.
Key words: coronary artery disease, cellular adhesion molecule, galectin-2, gene polymorphism, inflammation, lymphotoxin-α
(LTA), myocardial infarction.
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INTRODUCTION
Inflammation plays an important role in the development
and progression of atherosclerosis and is likely to play
a critical role in the pathogenesis of plaque rupture
which precedes a myocardial infarction [1]. The pro-
inflammatory cytokine LTA [lymphotoxin-α; or TNF
(tumour necrosis factor)-β] is found in atherosclerotic le-
sions [2] and may contribute to these processes. Further-
more, LTA may also induce adhesion molecules and
cytokines from vascular endothelial and smooth muscle
cells [3]. A large-scale association study from the
Japanese Osaka Acute Coronary Insufficiency Study
group identified functional SNPs (single nucleotide poly-
morphisms) within the LTA gene that were associated
with a risk of myocardial infarction [LTA C804A (result-
ing in a Thr26 → Asp amino acid substitution) and LTA
A252G] [4]. Among these SNPs, the LTA C804A poly-
morphism induced an almost 2-fold higher expression of
E-selectin and VCAM-1 (vascular cell adhesion mole-
cule-1) in cultured human coronary artery smooth
muscle cells, and the presence of the LTA A252G gene
polymorphism was associated with a 1.5-fold greater
transcriptional activity of LTA [4]. The LTA and TNF
(encoding TNF-α) genes are in significant linkage dis-
equilibrium and are situated close to each other within
the HLA (human leucocyte antigen) class III cluster
on the short arm of chromosome 6.
Several other studies have examined the association
between LTA gene polymorphisms and CHD (coronary
heart disease), but these studies were based on identific-
ation of prevalent cases and the results were inconsistent
[5–10]. In addition, genotype distribution in the
original study by Ozaki et al. [4] deviated from
Hardy–Weinberg equilibrium in the control group. A
prospective longitudinal study is needed to investigate
the association between LTA gene polymorphisms and
CHD. Furthermore, the relationship between LTA
gene polymorphisms and plasma levels of inflammatory
markers and cell adhesion molecules are unknown.
Recently, the Japanese Osaka Acute Coronary Insuffi-
ciency Study group identified the galectin-2 protein as
a regulator of LTA protein secretion and, therefore, also
potentially important in modifying the degree of inflam-
mation [3]. Both LTA and galectin-2 are expressed in
smooth muscle cells and macrophages in the intima of
atherosclerotic lesions of the coronary artery. Further-
more, the functional SNP (C3279T) in the galectin-2
(LGALS2) gene may be inversely associated with a risk
of myocardial infarction [3]. No study has yet replicated
these results in a prospective design.
We hypothesize that the common C804A and A252G
polymorphisms of the LTA gene and the C3279T poly-
morphism of the LGALS2 gene are associated with
circulating inflammatory markers and cell adhesion
molecules [i.e. CRP (C-reactive protein), IL-6 (inter-
leukin-6), sTNF-R1 (soluble TNF receptor 1), sTNF-
R2, VCAM-1 and E-selectin] and we aim to investigate
whether these polymorphisms are related to CHD in a




We conducted a prospective nested case-control
study within the NHS (Nurses’ Health Study) and
HPFS (Health Professionals Follow-Up Study). Among
participants free of cardiovascular disease at baseline, 249
women and 266 men developed non-fatal myocardial
infarction or fatal CHD during 8 and 6 years of follow-
up respectively. As a secondary end point, we addi-
tionally identified 564 men who had CABG (coronary
artery bypass graft surgery) or PTCA (percutaneous
transluminal coronary angioplasty) during follow-up.
Myocardial infarction was confirmed using World Health
Organization criteria. Deaths were identified from State
vital records and the National Death Index, or were
reported by subjects’ next of kin or the postal system.
Fatal CHD was confirmed by hospital records or on
autopsy, or if CHD was listed as the cause of death
on the death certificate, if it was the underlying and most
plausible cause, and if evidence of previous CHD was
available. Confirmation of CABG/PTCA was based on
self-reporting only. The study protocol was approved
by the Institutional Review Board of the Brigham and
Women’s Hospital and the Harvard School of Public
Health Human Subjects Committee Review Board; all
participants provided informed consent.
Controls were selected 2:1 matched for age, smoking
and month of blood draw. In addition, female controls
were matched for fasting status. Biomarkers were
measured for non-fatal myocardial infarction and fatal
CHD cases and their controls only (the set of CABG/
PTCA cases and controls did not have available plasma
biomarkers).
Laboratory methods
CRP concentrations were determined using an immuno-
turbidimetric high-sensitivity assay (Denka Seiken) with
day-to-day assay variability between 1 and 2 %. Levels
of IL-6, sTNF-R1, sTNF-R2, VCAM-1 and E-selectin
were measured by ELISA (R&D Systems) [11], which
have a day-to-day variability of 3.5–9.0 %. HDL (high-
density lipoprotein)-cholesterol and directly obtained
LDL (low-density lipoprotein)-cholesterol were mea-
sured using standard methods with reagents from Roche
Diagnostics and Genzyme.
Genotyping of polymorphisms
DNA was extracted from the buffy coat fraction of
centrifuged blood using the QIAmp Blood Kit (Qiagen).
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Table 1 Baseline characteristics of women and men who developed non-fatal myocardial infarction or fatal CHD during
follow-up (cases) and matched event-free controls
Continuous variables are means+− S.E.M., except for CRP, IL-6 and E-selectin, which are medians (interquartile range). Men I, men who developed non-fatal myocardial
infarction or fatal CHD during follow-up. MI, myocardial infarction.
Women Men I
Variable Cases (n = 249) Controls (n = 498) P value Cases (n = 266) Controls (n = 522) P value
Age (years) 60.4+− 0.4 60.3+− 0.3 Matched 65.2 +− 8.3 65.1+− 8.3 Matched
Current smoker (%) 32.1 31.9 Matched 12.0 12.1 Matched
Caucasians (%) 96.1 96.5 0.64 98.1 98.2 0.42
Diabetes (%) 19.7 6.6 < 0.001 9.4 4.5 0.007
History of hypertension (%) 57.4 29.3 < 0.001 42.1 30.9 0.002
BMI (kg/m2) 26.8+− 0.4 25.4+− 0.2 < 0.001 26.2 +− 0.2 25.7+− 0.2 0.06
Family history of MI (%) 27.7 12.3 < 0.001 51.5 37.3 < 0.001
HDL-cholesterol (mg/dl) 51.7+− 0.9 60.3+− 0.8 < 0.001 42.1+− 0.7 45.9+− 0.5 < 0.001
HDL-cholesterol (mmol/l) 1.32+− 0.02 1.55+− 0.02 − 1.08+− 0.02 1.18+− 0.01 −
LDL-cholesterol (mg/dl) 143.0+− 2.26 132.3+− 1.7 < 0.001 135.6+− 2.2 126.8+− 1.4 < 0.001
LDL-cholesterol (mmol/l) 3.67+− 0.0 3.39+− 0.04 − 3.48+− 0.06 3.25+− 0.04 −
CRP (mg/l) 3.12 (1.30–7.50) 2.20 (1.00–5.23) < 0.001 1.68 (0.76–3.15) 1.08 (0.52–2.40) < 0.001
IL-6 (pg/ml) 1.99 (1.30–3.04) 1.66 (1.16–2.67) 0.002 1.86 (1.10–3.07) 1.53 (0.97–2.88) 0.008
sTNF-R1 (pg/ml) 1447+− 38 1270+− 16 < 0.001 1514+− 31 1504+− 23 0.81
sTNF-R2 (pg/ml) 2790+− 64 2491+− 32 < 0.001 2992+− 53 2943+− 38 0.45
VCAM-1 726+− 171 703+− 157 0.13 1364+− 331 1311+− 318 0.03
E-selectin 49.4 (35.6–63.7) 44.1 (31.7–56.8) 0.001 – – –
We studied two SNPs in the LTA gene on chromosome
6p21 (HLA cluster): the LTA C804A (rs1041981) in exon
3 (resulting in the amino acid substitution Thr26 → Asn)
and LTA A252G (rs909253) in intron 1. In addition,
we genotyped the C3279T (rs7291467) polymorphism
in intron 1 of the LGALS2 gene on chromosome 22q
using Taqman SNP allelic discrimination by means of an
ABI 7900HT (Applied Biosystems). Primer and probe
sequences are available on request.
Statistical analysis
Continuous data are reported as means +− S.E.M. or
medians (interquartile range) if the data were skewed.
Categorical data are presented as per group percentages.
Differences between subgroups were evaluated by
Student’s t test for the normally distributed continuous
variables or by the Mann–Whitney test if data were
skewed. Differences in genotype frequencies and other
categorical data between cases and controls were com-
pared with the χ 2 test or Fisher’s exact test. Consistency
of genotype frequencies with the Hardy–Weinberg
equilibrium was tested using a χ 2 goodness-of-fit test on
a contingency table of observed compared with expected
genotype frequencies in cases and controls. Genotype–
phenotype associations were examined with additive,
dominant and recessive models using multivariate logistic
regression analyses. Odds ratios for the occurrence of
CHD and their 95 % CIs (confidence intervals) were
calculated after adjustment for matching factors. Linear
mixed models were used to investigate the age-adjusted
association between genotypes and inflammatory mark-
ers. In addition, linear mixed models were used to
investigate the gene–environment interaction between
BMI (body mass index) and LTA and LGALS2 gene
polymorphisms on inflammatory markers. All results
were considered statistically significant if the two-sided
P value for the test statistic was less than or equal to
the set type I error rate (α) of 0.05. No adjustment for
multiple comparisons was performed, because there were
few statistical tests and there is good biological evidence
that each of the biochemical systems being studied is
functionally involved in regulating inflammatory status
either directly or indirectly, suggesting the universal
null hypothesis that is assumed for a Bonferroni-type
correction does not apply to these data [12]. Analyses
were performed using SAS version 9.1 (SAS Institute).
RESULTS
Baseline characteristics
The general characteristics of both the NHS as well
as the HPFS, divided on the basis of cases and controls,
are shown in Table 1. Cases were more likely to have
diabetes, hypertension and a family history of myocardial
infarction than matched controls. In addition, cases
from both studies had significantly higher levels of
LDL-cholesterol and lower levels of HDL-cholesterol.
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Table 2 Genotype distributions among women who developed non-fatal myocardial infarction or fatal CHD during follow-
up (cases) and matched event-free controls, and among men in groups I (Men I) and II (Men II) and matched event-free
controls
Men I, men who developed non-fatal myocardial infarction or fatal CHD during follow-up; Men II, men in the Men I group (n = 266) plus men who underwent CABG
or PTCA during follow-up (n = 564). P value for comparison between cases and controls.
Women Men I Men II
Genotype Cases Controls Cases Controls Cases Controls
LTA C804A (n)
AA 101 (43.9 %) 208 (44.2 %) 118 (47.8 %) 221 (44.5 %) 384 (49.9 %) 720 (46.2 %)
CA 95 (41.3 %) 213 (45.2 %) 100 (40.5 %) 223 (44.9 %) 304 (39.5 %) 691 (44.4 %)
CC 34 (14.8 %) 50 (10.6 %) 29 (11.7 %) 53 (10.7 %) 81 (10.5 %) 145 (9.3 %)
P value 0.42 0.67 0.39
LTA A252G (n)
AA 103 (43.5 %) 207 (44.9 %) 119 (46.5 %) 223 (44.4 %) 389 (49.2 %) 730 (46.0 %)
AG 98 (41.4 %) 199 (43.2 %) 106 (41.4 %) 225 (44.8 %) 320 (40.5 %) 708 (44.6 %)
GG 36 (15.2 %) 55 (11.9 %) 31 (12.1 %) 54 (10.8 %) 82 (10.4 %) 148 (9.3 %)
P value 0.39 0.89 0.46
LGALS2 C3279T (n)
CC 102 (43.8 %) 162 (34.8 %) 72 (28.6 %) 170 (33.9 %) 230 (29.5 %) 506 (32.2 %)
CT 99 (42.5 %) 220 (47.3 %) 133 (52.8 %) 232 (46.2 %) 394 (50.5 %) 749 (47.6 %)
TT 32 (13.7 %) 83 (17.9 %) 47 (18.7 %) 100 (19.9 %) 157 (20.1 %) 319 (20.3 %)
P value 0.02 0.46 0.41
Women with CHD had a higher BMI and higher
levels of inflammatory markers, including CRP, IL-6,
sTNF-R1, sTNF-R2 and E-selectin, than the matched
control group. Men with CHD had significantly higher
levels of CRP, IL-6 and VCAM-1, but mean sTNF-
R1 and sTNF-R2 levels were not different between the
groups. The characteristics did not change substantially
when including men and matched controls who needed
cardiac revascularization, the secondary end point
(Men II). The distributions of genotypes were in Hardy–
Weinberg equilibrium both in cases as well as controls
(P > 0.10). The genotype frequencies are shown in
Table 2. Only the distribution of the LGALS2 gene
polymorphism was significantly different between female
cases compared with matched event-free controls. The
pairwise linkage disequilibrium (D′) and the correlation
coefficient between LTA C804A and LTA A252G were
0.99. No correlation was present between the LTA gene
polymorphisms and LGALS2 gene polymorphism.
Association between LTA and LGALS2 gene
polymorphisms and markers of
inflammation and cell adhesion molecules
Tables 3–5 show the age-adjusted levels of the inflammat-
ory markers and cell adhesion molecules (i.e. CRP, IL-6,
sTNF-R1, sTNF-R2, VCAM-1 and E-selectin) among
the different genotypes. The LTA C804A polymorphism
was associated with plasma levels of sTNF-R2 and
VCAM-1 in both female and male cases. In addition, the
LTA C804A gene polymorphism was significantly asso-
ciated with IL-6 in men without CHD (Table 3). Similar
results were found for the LTA A252G gene poly-
morphism, which was also associated with sTNF-R1
levels in both women as well as men with CHD
(Table 4).The LGALS2 gene polymorphism was asso-
ciated with CRP levels in both male and female cases
(Table 5). Furthermore, no significant interaction was
present between BMI and the gene polymorphisms on
the inflammatory markers in cases or controls from
both the female and male cohorts.
Association between LTA and LGALS2 gene
polymorphisms and risk of CHD
Table 6 shows the results from unconditional multivariate
logistic regression analyses for CHD. The LGALS2 gene
variant was inversely associated with a risk of CHD in
women [odds ratio (95 % CI), 0.70 (0.50–0.97); P = 0.03].
This effect was independent of cardiovascular risk factors
predictive of cardiovascular disease (diabetes, history of
hypertension, BMI, family history of myocardial infarc-
tion, HDL-cholesterol, LDL-cholesterol, CRP, IL-6,
sTNF-R1, sTNF-R2, VCAM-1 and E-selectin). The odds
ratio (95 % CI) for CHD in women after adjustment for
all these factors was 0.36 (0.22–0.59) (P < 0.001). This
association was not present in men. After pooling the data
from both women and men, we found a significant gender
interaction between the LGALS2 gene polymorphism
and risk of CHD (P = 0.01 for interaction).
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Table 3 Biomarker levels adjusted for age according to LTA C804A (rs1041981) genotype among women and men
Variables are means+− S.E.M., except for CRP, IL-6 and E-selectin, which are geometric means (95 % CIs). ∗Additive model, P = 0.011; dominant model, P = 0.005;
recessive model, P = 0.860. †Additive model, P = 0.029; dominant model, P = 0.952; recessive model, P = 0.009. ‡Additive model, P = 0.018; dominant model,
P = 0.050; recessive model, P = 0.728. §Additive model, P = 0.194; dominant model, P = 0.471; recessive model, P = 0.076. ¶Additive model, P = 0.103;
dominant model, P = 0.847; recessive model, P = 0.038. ‖Additive model, P = 0.102; dominant model, P = 0.865; recessive model, P = 0.042. Men I, men who
developed non-fatal myocardial infarction or fatal CHD during follow-up.
(a) Cases
Women Men I
Variable Genotype . . . AA CA CC AA CA CC
CRP 2.73 (2.21–3.36) 3.46 (2.70–4.43) 3.40 (2.31–5.01) 1.59 (1.30–1.94) 1.66 (1.39–1.99) 1.61 (1.05–2.47)
IL-6 1.99 (1.77–2.23) 2.15 (1.86–2.48) 1.92 (1.50–2.46) 2.36 (1.94–2.88) 2.07 (1.77–2.43) 2.09 (1.51–2.89)
sTNF-R1 1358+− 45 1509+− 66 1417+− 98 1509+− 46 1485+− 40 1624+− 92
sTNF-R2 2568+− 74 2960+− 106 2726+− 151∗ 2968+− 73 2930+− 77 3400+− 161†
VCAM-1 694+− 17 769 +− 680 680+− 39‡ 1346+− 25 1352+− 39 1456+− 56§
E-selectin 46.6 (42.6– 51.1) 49.8 (45.7– 54.3) 43.6 (38.2– 49.7) − − −
(b) Controls
Women Men I
Variable Genotype . . . AA CA CC AA CA CC
CRP 2.18 (1.90–2.51) 2.27 (1.92–2.69) 2.01 (1.48–2.73) 1.18 (1.01–1.38) 1.23 (1.05–1.44) 0.96 (0.07–1.28)
IL-6 1.75 (1.59–1.92) 1.90 (1.73–2.08) 1.66 (1.39–1.99) 1.83 (1.60–2.09) 1.88 (1.68–2.10) 1.50 (1.24–1.80)¶
sTNF-R1 1272+− 24 1272+− 23 1215+− 52 1476+− 32 1539+− 36 1466+− 58
sTNF-R2 2493+− 45 2503+− 49 2426+− 100 2931+− 54 2953+− 51 2816+− 118
VCAM-1 715+− 12 694 +− 13 695+− 29 1303+− 19 1325+− 22 1234+− 37‖
E-selectin 41.4 (39.1– 43.9) 43.8 (41.4– 46.3) 42.5 (37.6– 48.1) − − −
DISCUSSION
In the present large prospective nested case-control
study among American women and men, we investigated
the relationship between LTA and LGALS2 gene
polymorphisms and levels of inflammatory markers, cell
adhesion molecules and risk of CHD. This study showed
significant associations between the polymorphisms in
the LTA and LGALS2 genes and markers of inflammation
and cell adhesion molecules, but no association was found
between LTA gene polymorphisms and risk of CHD in
women and men. For the LGALS2 gene polymorphism,
we found evidence of a significant gender interac-
tion, with a significant association for women, but not
men, with the risk of CHD.
Previous case-control and cross-sectional studies have
examined the association between LTA gene polymor-
phisms and cardiovascular disease, but the results are
inconsistent. The first study by Ozaki et al. [4] described
significant associations between LTA gene polymorph-
isms and myocardial infarction; however, the authors did
not adjust for relevant covariates, including gender and
age, and the genotype distributions among the control
subjects were not in Hardy–Weinberg equilibrium.
The association between the LTA gene polymorphisms
and CHD was confirmed in another Japanese population
[5] and in the family-based European PROCARDIS
(precocious coronary artery disease) study [6]. Further-
more, a significant association was found between the
LTA C804A genotype and the extent of coronary athero-
sclerosis in Caucasian patients with angiographically con-
firmed coronary atherosclerosis [7]. In concordance with
the present results, several other studies did not detect an
association between LTA gene polymorphisms and myo-
cardial infarction [8–10], and our findings are in agree-
ment with a recent meta-analysis performed by Clarke
et al. [10], which showed no relationship between LTA
gene polymorphisms and CHD. In contrast with the pre-
vious reports included in this meta-analysis, we used un-
related controls selected from the same population as the
cases.
Our present study has shown a significant association
between the LGALS2 gene polymorphism and reduced
risk for CHD in women; however, this association could
not be replicated in our male population. This statistical
gender interaction might be a true biological interaction
or may reflect differences in cardiovascular risk factors
in the male and female study populations. The present
study is in concordance with the findings of Ozaki et al.
[3], who reported an association between the LGALS2
gene polymorphism and myocardial infarction. However,
their study did not provide any information about gender
differences. Other functional studies published so far do
not report differences in LTA secretion between genders,
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Table 4 Biomarker levels adjusted for age according to LTA A252G (rs909253) genotype among women and men
Variables are means+− S.E.M., except for CRP, IL-6 and E-selectin, which are geometric means (95 % CIs). ∗Additive model, P = 0.028; dominant model, P = 0.014;
recessive model, P = 0.676. †Additive model, P = 0.002; dominant model, P = 0.001; recessive model, P = 0.606. ‡Additive model, P = 0.056; dominant model,
P = 0.384; recessive model, P = 0.016. §Additive model, P = 0.009; dominant model, P = 0.017; recessive model, P = 0.342. ¶Additive model, P = 0.128;
dominant model, P = 0.379; recessive model, P = 0.049. ‖Additive model, P = 0.111; dominant model, P = 0.872; recessive model, P = 0.042. Men I, men who
developed non-fatal myocardial infarction or fatal CHD during follow-up.
(a) Cases
Women Men I
Variable Genotype . . . AA AG GG AA AG GG
CRP 2.63 (2.12–3.26) 3.62 (2.84–4.62) 3.22 (2.17–4.77) 1.62 (1.33–1.98) 1.64 (1.38–1.94) 1.49 (0.99–2.24)
IL-6 1.97 (1.75–2.20) 2.17 (1.90–2.48) 1.87 (1.45–2.40) 2.27 (1.87–2.76) 2.08 (1.77–2.44) 1.96 (1.43–2.67)
sTNF-R1 1344+− 44 1562+− 68 1407+− 93∗ 1493+− 43 1497+− 39 1604+− 87
sTNF-R2 2553+− 72 3051+− 117 2711+− 144† 2933+− 73 2929+− 74 3332+− 157‡
VCAM-1 694+− 17 776+− 21 696+− 40§ 1340+− 25 1350+− 36 1457+− 53¶
E-selectin 46.3 (42.5–50.5) 50.0 (45.8–54.6) 43.6 (38.4–49.4) − − −
(b) Controls
Women Men I
Variable Genotype . . . AA AG GG AA AG GG
CRP 2.17 (1.88–2.50) 2.35 (1.98–2.80) 1.92 (1.46–2.54) 1.19 (1.02–1.40) 1.22 (1.05–1.43) 0.95 (0.72–1.27)
IL-6 1.75 (1.59–1.93) 1.93 (1.76–2.13) 1.67 (1.41–1.99) 1.83 (1.61–2.09) 1.89 (1.69–2.10) 1.51 (1.26–1.81)‖
sTNF-R1 1268+− 24 1277+− 24 1261+− 52 1481+− 31 1535+− 36 1479+− 57
sTNF-R2 2492+− 45 2503+− 52 2553+− 106 2950+− 54 2956+− 52 2895+− 121
VCAM-1 715+− 12 688+− 13 717+− 32 1307+− 19 1328+− 22 1255+− 41
E-selectin 42.2 (39.7–44.8) 43.4 (40.9–46.0) 42.9 (37.8–48.7) − − −
Table 5 Biomarker levels adjusted for age according to LGALS2 C3279T (rs7291467) genotype among women and men
Variables are means+− S.E.M., except for CRP, IL-6 and E-selectin, which are geometric means (95 % CIs). ∗Additive model, P = 0.035; dominant model, P = 0.041;
recessive model, P = 0.507. †Additive model, P = 0.051; dominant model, P = 0.017; recessive model, P = 0.281. Men I, men who developed non-fatal myocardial
infarction or fatal CHD during follow-up.
(a) Cases
Women Men I
Variable Genotype . . . CC CT TT CC CT TT
CRP 2.61 (2.06–3.29) 3.88 (3.15–4.78) 2.73 (1.80–4.14)∗ 1.26 (1.02–1.56) 1.71 (1.42–2.05) 1.84 (1.37–2.47)†
IL–6 2.09 (1.82–2.40) 2.14 (1.90–2.40) 1.97 (1.49–2.60) 1.81 (1.54–2.12) 2.36 (1.97–2.82) 2.01 (1.55–2.59)
sTNF-R1 1426+− 58 1447+− 60 1468+− 103 1478+− 51 1490+− 38 1557+− 63
sTNF-R2 2765+− 105 2802+− 91 2847+− 177 3017+− 94 2920+− 70 3071+− 94
VCAM-1 721+− 20 736 +− 22 702+− 31 1412+− 36 1329+− 26 1392+− 57
E-selectin 46.1 (42.3– 50.1) 48.8 (44.5– 53.4) 51.0 (44.1– 59.1) − − −
(b) Controls
Women Men I
Variable Genotype . . . CC CT TT CC CT TT
CRP 2.12 (1.80–2.49) 2.15 (1.83–2.54) 2.35 (1.87–2.94) 1.27 (1.06–1.52) 1.16 (1.01–1.34) 1.03 (0.80–1.34)
IL-6 1.79 (1.63–1.98) 1.85 (1.67–2.04) 1.75 (1.52–2.01) 1.92 (1.68–2.20) 1.70 (1.54–1.88) 1.94 (1.56–2.41)
sTNF-R1 1250+− 25 1273+− 24 1311+− 38 1513+− 34 1494+− 34 1512+− 56
sTNF-R2 2453+− 50 2513+− 50 2525+− 67 3000+− 64 2870+− 51 3006+− 82
VCAM-1 712+− 16 698 +− 11 692+− 23 1316+− 27 1297+− 19 1332+− 26
E-selectin 43.2 (40.5– 46.2) 41.5 (39.1– 44.0) 46.5 (42.5– 50.8) − − −
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Table 6 Associations of LTA and LGALS2 gene polymorphisms with risk of CHF
Values are odds ratios (95 % CIs). Men I, men who developed non-fatal myocardial infarction or fatal CHD during follow-up; Men II, men in the Men I group (n = 266)
plus men who underwent CABG or PTCA during follow-up (n = 564). P value for comparison between cases and controls. ∗P = 0.0252; †P = 0.0312.
Women Men I Men II Pooled (women and men I)
LTA C804A
Additive 1.08 (0.85–1.36) 0.95 (0.76–1.20) 0.94 (0.82–1.07) 0.99 (0.84–1.17)
Dominant 0.98 (0.71–1.36) 0.87 (0.64–1.82) 0.86 (0.72–1.02) 0.92 (0.74–1.15)
Recessive 1.42 (0.88–2.28) 1.13 (0.70–1.84) 1.15 (0.86–1.54) 1.20 (0.86–1.67)
LTA A252G
Additive 1.08 (0.86–1.36) 0.99 (0.79–1.24) 0.95 (0.83–1.08) 1.03 (0.87–1.20)
Dominant 1.04 (0.75–1.43) 0.92 (0.68–1.25) 0.88 (0.74–1.04) 0.96 (0.77–1.19)
Recessive 1.29 (0.81–2.05) 1.15 (0.72–1.85) 1.13 (0.85–1.50) 1.15 (0.84–1.59)
LGALS2 C3279T
Additive 0.77 (0.61–0.97)∗ 1.09 (0.88–1.35) 1.05 (0.93–1.19) 0.94 (0.80–1.10)
Dominant 0.70 (0.50–0.97)† 1.29 (0.92–1.79) 1.14 (0.94–1.37) 0.94 (0.75–1.19)
Recessive 0.72 (0.46–1.13) 0.93 (0.63–1.37) 1.00 (0.80–1.23) 0.87 (0.64–1.17)
but, as shown in Table 1, levels of inflammatory markers
differ between genders and, therefore, it is possible
that LTA has a sex-specific range too. Future studies
are needed to investigate whether LTA secretion differs
between genders.
Surprisingly, no relationship was found between LTA
gene polymorphisms and CRP. LTA is a pro-inflammat-
ory cytokine acting through activation of NF-κB (nuclear
factor κB), and previous reports have demonstrated a
weak, but significant, association between an LTA gene
polymorphism and CRP levels [10,13]. Galectin-2 has
been shown [3] to affect LTA expression levels and might
therefore influence CRP levels as well; however, the re-
lationship between LGALS2 genotype and CRP in the
present study was opposite to that expected. We cannot
exclude the role of chance or some counter-regulatory
action which we did not capture with the genetic variation
in LGALS2. Clearly, further study is needed to confirm
or reject the present findings.
Interestingly, we found a significant association be-
tween LTA gene polymorphisms and the level of sTNF-
R2 in both women and men. LTA is a pro-inflammatory
cytokine that may contribute to atherosclerosis by activ-
ation of growth factors and cytokines, and by affecting
the synthesis and stimulation of adhesion molecules [4].
LTA, like TNF-α, interacts with sTNF-R1 and sTNF-
R2. sTNF-R concentrations are increased in patients with
infectious diseases and may be useful as an indicator of
LTA-induced inflammation [14]. On the other hand, the
observed association between LTA gene polymorphisms
and inflammatory markers might also represent an effect
of the TNF gene or other genetic products of the HLA
cluster, because the LTA gene is in significant linkage
disequilibrium with the TNF gene located on chromo-
some 6 and the HLA cluster [15].
Furthermore, we detected a weak association between
VCAM-1 and LTA gene polymorphisms; however, the
direction of the associations between VCAM-1 and LTA
gene polymorphisms found in the present study were not
consistent among the cohorts. In contrast with the males,
the variant genotype was associated with lower VCAM-
1 levels in the female cases. This might be due to chance
considering the borderline significance levels or indicate
a true gender difference. Ozaki et al. [4] demonstrated
previously that variant protein LTA 26A induced an
increase in VCAM-1 and E-selectin in human coronary
artery vascular smooth muscle cells. Elevated expression
of adhesion molecules, such as VCAM-1 and E-selec-
tin, might contribute to the pathogenesis of myocardial
infarction, but despite the association between LTA gene
polymorphisms and VCAM-1 no relationship between
LTA gene polymorphisms and CHD could be demon-
strated in the present study.
In conclusion, the present study has demonstrated an
association between LTA and LGALS2 gene polymor-
phisms and markers of inflammation and cell adhesion
molecules, but did not detect a significant association
between LTA gene polymorphisms and CHD in
American women and men. Future studies are needed to
replicate the observed association between the LGALS2
gene polymorphism and reduced risk of CHD in
women.
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